Linvoseltamab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CD3 and BCMA |
| Clinical data | |
| Trade names | Lynozyfic |
| Other names | REGN5458, REGN-5458, linvoseltamab-gcpt |
| AHFS/Drugs.com | Lynozyfic |
| License data | |
| Routes of administration | Intravenous |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6455H9955N1721O2039S47 |
| Molar mass | 145800.47 g·mol−1 |
Linvoseltamab, sold under the brand name Lynozyfic, is an anti-cancer medication used for the treatment of people with relapsed or refractory multiple myeloma.[2][4] Linvoseltamab is a bispecific monoclonal antibody that targets CD3 and B-cell maturation antigen (BCMA) (TNFRSF17).[2] It is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager and a recombinant human immunoglobulin (Ig)G4 antibody.[1][5]
Lynozyfic was authorized for medical use in the European Union in April 2025,[2][3] and approved for medical use in the United States in July 2025.[5]
- ^ a b https://www.regeneron.com/downloads/lynozyfic_fpi.pdf
- ^ a b c d Cite error: The named reference
Lynozyfic EPARwas invoked but never defined (see the help page). - ^ a b Cite error: The named reference
Lynozyfic PIwas invoked but never defined (see the help page). - ^ Avigan ZM, Rattu MA, Richter J (February 2025). "An evaluation of linvoseltamab for treatment of relapsed/refractory multiple myeloma". Expert Opinion on Biological Therapy. 25 (3): 221–228. doi:10.1080/14712598.2025.2465825. PMID 39923122.
- ^ a b "FDA grants accelerated approval to linvoseltamab-gcpt for relapsed or refractory multiple myeloma". U.S. Food and Drug Administration (FDA). 2 July 2025. Retrieved 4 July 2025. This article incorporates text from this source, which is in the public domain.